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Abstract
Background: This study included a network meta-analysis of evidence from randomized controlled trials (RCTs) to
assess the therapeutic outcome of transurethral resection (TUR) in patients with non-muscle-invasive bladder cancer
assisted by photodynamic diagnosis (PDD) employing 5-aminolaevulinic acid (5-ALA) or hexylaminolevulinate (HAL)
or by narrow band imaging (NBI).
Methods: Relevant RCTs were identified from electronic databases. The proceedings of relevant congresses were
also searched. Fifteen articles based on RCTs were included in the analysis, and the comparisons were made by
qualitative and quantitative syntheses using pairwise and network meta-analyses.
Results: Seven of 15 RCTs were at moderate risk of bias for all quality criteria and two studies were classified as
having a high risk of bias. The recurrence rate of cancers resected with 5-ALA-based PDD was lower than of those
resected using HAL-based PDD (odds ratio (OR) = 0.48, 95 % confidence interval (CI) [0.26–0.95]) but was not
significantly different than those resected with NBI (OR = 0.53, 95 % CI [0.26–1.09]). The recurrence rate of cancers
resected using HAL-based PDD versus NBI did not significantly differ (OR = 1.11, 95 % CI [0.55–2.1]). All cancers
resected using 5-ALA-based PDD, HAL-based PDD, or NBI recurred at a lower rate than those resected using white
light cystoscopy (WLC). No difference in progression rate was observed between cancers resected by all methods
investigated.
Conclusions: The recurrence rate of some bladder cancers can be decreased by the implementation of either
PDD- and NBI-assisted TUR; in real settings, clinicians should consider replacing WLC as the standard imaging
technology to guide TUR.
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Background
The conventional therapy for non-muscle invasive bladder
cancer (NMIBC) is based on transurethral resection
(TUR) combined with post-operational chemotherapy or
immunotherapy with Bacille Calmette-Guérin [1]. Con-
ventional white light cystoscopy (WLC) has been the
standard method for detecting urothelial carcinoma
during TUR [2]. However, the sensitivity and specifi-
city of WLC is not entirely satisfactory [3]. Flat malig-
nant lesions including carcinoma in situ (CIS) are
difficult to visualize and distinguish from benign in-
flammatory lesions.
New imaging technologies including photodynamic diag-
nosis (PDD) and narrow band imaging (NBI) have recently
been introduced; these technologies enhance bladder can-
cer visualization to improve diagnostic accuracy and the
thoroughness of resection. PDD involves the instillation of
photoactive porphyrin precursors such as 5-aminolaevulinic
acid (5-ALA) or hexylaminolevulinate (HAL), which are
metabolized to the photoactive compound intracellularly
and then emit red fluorescence under blue light. NBI fil-
ters white light into two discrete bands in the blue and
green spectrums that penetrate tissue only superficially
but are strongly absorbed by hemoglobin. Both PDD and
NBI are macroscopic modalities and can thus survey a
large area of bladder mucosa in a manner similar to WLC,
while providing additional contrast enhancement to high-
light suspicious lesions and distinguish them from sur-
rounding, noncancerous mucosa. Several studies have
demonstrated that PDD and NBI are more sensitive than
WLC in detecting small papillary bladder tumors and CIS,
thus improving tumor detection rates and decreasing re-
sidual tumor rates. This study assessed the therapeutic out-
come of PDD- or NBI-assisted TUR in patients with
NMIBC via a network meta-analysis of evidence from ran-
domized controlled trials (RCTs).
Methods
Inclusion criteria
Published RCTs that met the following criteria were
included: (i) a study design that included measurement
of the clinical efficacy of PDD or NBI and compared it
with that of WLC in patients with suspected or con-
firmed NMIBC, (ii) a match between the baseline char-
acteristics of patients from two groups, including the
total number of subjects and the values of each index,
(iii) the performance of the procedure under general
anesthesia, spinal anesthesia, or combined spinal–epi-
dural anesthesia, (iv) the assessment of at least one of
the following outcomes: recurrence rate defined as the
number of bladder cancer recurrences after initial
TUR, progression rate defined as the number of pa-
tients with disease progression into muscle invasive
bladder cancer during the follow-up period, or time
until first recurrence, defined as the time until bladder
cancer recurrence after initial TUR, and (v) accessibility to
the study’s full text in English. When two or more studies
reported on a group of patients at the same institution
during an overlapping time period, only the study with the
longest follow-up period was included. This report was
prepared in compliance with Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) state-
ment (accessible at http://www.prisma-statement.org/) [4].
Search strategy
A literature search was performed across all publications
prior to 31 December 2013 in PubMed, and EMBASE™
online databases. A cross-reference search of eligible
articles was performed to identify additional studies not
found by the computerized search. A combination of the
following MeSH terms and keywords was used: fluores-
cence cystoscopy, photodynamic diagnoses, narrow, im-
aging, bladder cancer/tumor, white light cystoscopy, and
randomized controlled trial.
Data extraction
One researcher (J.Y.L.) screened the titles and abstracts
identified by the search strategy. The other two re-
searchers (D.H.K. and K.S.C.) independently assessed
each paper’s full text to determine whether a paper met
the inclusion criteria. The databases were designed to
include the most relevant data with respect to author,
year of publication, patient demographics, treatments,
recurrence and progression outcomes, and inclusion of a
reference standard. Disagreements were resolved by dis-
cussion until a consensus was reached or by arbitration
employing another researcher (Y.D.C.).
Study quality assessment and publication bias
Once the final group of articles was agreed upon, two
researchers (J.Y.L. and D.H.K.) independently examined
the quality of each article using the Cochrane’s risk of
bias as a quality assessment tool for RCTs. The assess-
ment includes assigning a judgment of “yes,” “no,” or
“unclear” for each domain to designate a low, high, or
unclear risk of bias, respectively. If one or no domain
was deemed “unclear” or “no,” the study was classified
as having a low risk of bias. If four or more domains are
deemed “unclear” or “no,” the study was classified as
having a high risk of bias. If two or three domains were
deemed “unclear” or “no,” the study was classified as
having a moderate risk of bias [5]. Publication bias was
examined using funnel plots. In the absence of publica-
tion bias, this method assumes that the largest studies
will be plotted near the average and that smaller studies
will be spread evenly on both sides of the average, creat-
ing a roughly funnel-shaped distribution. Deviation from
this shape can indicate publication bias. Quality
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assessment and investigation of publication bias were
carried out using Review Manager 5 (RevMan 5.2.3,
Cochrane Collaboration, Oxford, UK).
Heterogeneity tests
Heterogeneity among the studies was explored using the
Q-statistic and Higgins’ I2 statistic [6]. An I2 measures the
percentage of total variation due to heterogeneity rather
than chance across studies and is calculated as follows:
I2 ¼ Q‐df
Q
 100%
where “Q” is Cochran’s heterogeneity statistic and “df”
indicates the degrees of freedom.
An I2 ≥ 50 % was considered to represent substantial
heterogeneity. For the Q statistic, heterogeneity was
deemed to be significant for p less than 0.10 [7]. If there
was evidence of heterogeneity, the data were analyzed
using a random-effects model. Studies in which positive
results were confirmed were assessed with a pooled speci-
ficity with 95 % CIs.
Statistical analysis
Outcome variables measured at specific time points
were compared in terms of odds ratios (OR) or mean
differences with 95 % CIs using a network meta-analysis.
Each analysis was based on non-informative priors for
effect sizes and precision. Convergence and lack of auto-
correlation were checked and confirmed after four
chains and a 50,000-simulation burn-in phase; finally,
direct probability statements were derived from an add-
itional 100,000-simulation phase. Calculation of the
probability that each stent has the lowest rate of clinical
events was performed using Bayesian Markov Chain
Monte Carlo modeling. Sensitivity analyses were per-
formed by repeating the main computations using a
fixed effect method. Model fit was appraised by comput-
ing and comparing estimates for deviance and informa-
tion criterion. The existence of small study effects or
publication bias was assessed by visual inspection of fun-
nel plots for pairwise meta-analysis. All statistical analyses
were performed using Review Manager 5 and R (R version
3.0.2, R Foundation for Statistical Computing, Vienna,
Austria; http://www.r-project.org).
Results
Eligible studies
The database search found 41 articles covering 398 studies
for potential inclusion in the meta-analysis. Twenty-six
articles were excluded according to the inclusion/exclusion
criteria; 21 articles were retrospective models and 5 articles
were reported as case series. The remaining 15 articles were
included in the qualitative and quantitative synthesis using
pairwise and network meta-analyses (Fig. 1).
Data corresponding to confounding factors derived
from each study are summarized in Table 1 [8–22].
These studies covered therapeutic outcomes of TUR
assisted by three different types of PDD or NBI versus
WLC (Fig. 2).
Quality assessment and publication bias
Figure 3 presents the details of quality assessment, as
measured by the Cochrane Collaboration risk-of-bias
tool. Seven trials exhibited a moderate risk of bias for all
quality criteria and two studies were classified as having
a high risk of bias (Table 1). The most common risk fac-
tor for quality assessment was risk or insufficient infor-
mation concerning allocation concealment and the
second most common concerned random sequence gen-
eration. Most recently published studies exhibited low
risk for quality assessment. In terms of cancer recur-
rence and progression rate, little evidence of publication
bias was observed on visual or statistical examination of
the funnel plots (Fig. 4).
Heterogeneity assessment
Forest plots of pairwise meta-analyses are shown in Figs. 5
and 6. A heterogeneity test for recurrence rate showed the
following: χ2 = 3.21 with 3 df (P = 0.36) and I2 = 7 % in the
analysis of TUR assisted by 5-ALA-based PDD versus
WLC; χ2 = 4.25 with 4 df (P = 0.37) and I2 = 6 % in the
analysis of TUR assisted by HAL-based PDD versus WLC;
and χ2 = 0.42 with 3 df (P = 0.94) and I2 = 2 % in the meta-
analysis of diagnosis by NBI versus WLC. In the analysis
of progression rate, a heterogeneity test also demonstrated
homogeneity with χ2 = 0.08 with 4 df (P = 1.00) and I2 =
0 % in TUR assisted by 5-ALA-based PDD versus WLC
and χ2 = 1.01 with 3 df (P = 0.80) and I2 = 0 % in TUR
assisted by HAL-based PDD versus WLC. Because there
were no heterogeneities in these forest plots, the fixed
effect models were applied using the Mantel–Haenszel
method (Figs. 5 and 6).
Pairwise meta-analysis of rates of recurrence and
progression
The forest plot using the fixed effect model showed an
OR of 0.34 (95 % CI [0.22–0.51], P < 0.001) between the
recurrence rate of cancers resected using 5-ALA-based
PDD versus WLC. Pairwise meta-analysis of cancers
resected using HAL-based PDD versus WLC resulted in
an OR of 0.58 (95 % CI [0.45–0.74], P < 0.001). Accord-
ing to the forest plot for recurrence rate, NBI-guided
TUR was also superior to that using WLC, with an OR
of 0.47 (95 % CI [0.31–0.72], P < 0.001) (Fig. 5). How-
ever, in terms of progression rate, cancers resected using
5-ALA-based PDD, HAL-based PDD, or NBI did not
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significantly differ from those cancers resected using
WLC (all P > 0.05) (Fig. 6).
Network meta-analysis for rates of recurrence and
progression
The recurrence rate of cancers resected using 5-ALA-based
PDD was lower than that of those cancers resected using
HAL-based PDD (OR = 0.48, 95 % CI [0.26–0.95]) and was
not significantly different from those resected using NBI
(OR = 0.53, 95 % CI [0.26–1.09]). The recurrence rates of
cancers resected using HAL-based PDD versus NBI were
also not significantly different (OR = 1.11, 95 % CI [0.55–
2.1]). The use of 5-ALA-based PDD, HAL-based PDD, and
NBI all resulted in a lower recurrence rate than WLC
(Fig. 7a). Cancers resected using 5-ALA-based PDD occu-
pied the highest rank in the rank probability test for recur-
rence rate, followed by those resected using NBI (Fig. 8a).
No difference in progression rate was observed between
cancers resected using 5-ALA-based PDD, HAL-based
PDD, or NBI. Notably, TUR assisted by any of these tech-
niques did not significantly decrease the rate of progres-
sion over WLC-assisted TUR ( Fig. 7b). NBI-assisted TUR
was ranked highest in the rank probability test for
progression-free rate, followed by TUR using HAL-based
PDD (Fig. 8b); these rankings differed from those for
recurrence rate.
Discussion
Patients with tumors associated with CIS have a signifi-
cantly greater risk of progression [23]. WLC is the
current standard method for initial bladder cancer diag-
nosis but it has some disadvantages. These disadvantages
can influence the planning and execution of TUR and
may even influence the patient’s oncological outcomes.
Bladder cancer diagnosis using a new video technology
has recently being suggested as an alternative to over-
come WLC’s disadvantages. Substantial research has
been performed regarding diagnosis using a combination
of PDD and NBI with the new video methodology.
PDD requires the instillation of a protoporphyrin
derivative, typically a derivative of protoporphyrin IX
(PpIX), and its selective uptake by dysplastic cells [24].
Under blue light, abnormal cells containing PpIX fluor-
esce red. The two most common agents used for PPD
Fig. 1 Flow diagram of evidence acquisition. Fifteen studies were ultimately included in the qualitative and quantitative synthesis using pairwise
and network meta-analyses
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Table 1 Studies enrolled in this meta-analysis
Study Year Study
design
Method Cases Follow-up (mos.) Recurrence (%) Progression (%) Quality
assessmentaNIT WLC NIT WLC NIT WLC NIT WLC
Riedl [8] 2001 RCT 5-ALA 51 51 NA NA 22 (45.8) 31 (66) 1 (2) 1 (2) 3
Filbeck [9] 2002 RCT 5-ALA 88 103 21 21 10 (11.4) 29 (28.2) 2 (2.3) 2 (1.9) 3
Kriegmair [10] 2002 RCT 5-ALA 65 64 NA NA 17 (32.7) 26 (53.1) NA NA 2
Babjuk [11] 2005 RCT 5-ALA 60 62 21 22 5 (8.3) 23 (37.1) 5 (8.3) 5 (8.1) 3
Schumacher [12] 2010 RCT 5-ALA 138 141 12 12 NA NA 14 (10.1) 15 (10.6) 1
Stenzl [13] 2011 RCT 5-ALA 271 280 12 21 128 (47.2) 157 (56.1) 5 (1.8) 7 (2.5) 0
Dragoescu [14] 2011 RCT HAL 22 22 9 9 4 (18.2) 10 (45.5) 1 (4.5) 2 (9.1) 3
Hermann [15] 2011 RCT HAL 77 68 12 12 18 (30.5) 35 (47.3) 14 (34.1) 17 (37.8) 3
Stenzl [16] 2010 RCT HAL 183 176 12 12 NA NA 19 (10.4) 19 (10.8) 1
Geavlete [17] 2012 RCT HAL 125 114 24 24 39 (66.1) 52 (70.3) 5 (4) 8 (7) 1
Karaolides [18] 2012 RCT HAL 41 45 18 18 7 (17.1) 18 (40) NA NA 4
Geavlete [19] 2012 RCT NBI 110 110 12 12 7 (6.4) 16 (14.5) NA NA 3
Montanari [20] 2012 RCT NBI 47 45 NA NA 16 (34) 22 (48.9) NA NA 4
Naselli [21] 2012 RCT NBI 76 72 12 12 25 (32.9) 37 (51.4) NA NA 0
Lee [22] 2014 RCT NBI 33 35 16 15 5 (15.2) 8 (22.9) 1 (3) 2 (5.7) 1
NIT new image technology, WLC white light cystoscopy, RCT randomized controlled trial, NA not applicable, 5-ALA 5-aminolaevulinic acid, HAL hexylaminolevulinate,
NBI narrow band imaging
aQuality assessment was based on Cochrane’s risk of bias as a quality assessment tool for RCTs. If four or more domains are deemed “unclear” or “no,” the study
was classified as having a high risk of bias. If two or three domains were deemed “unclear” or “no,” the study was classified as having a moderate risk of bias
Fig. 2 Network plots for included studies. Six studies compared TUR using 5-ALA-based PDD versus TUR with WLC. Five trials reported on therapeutic
outcomes after TUR with HAL-based PDD versus TUR with WLC. Four studies included two arms of TUR with NBI and WLC were published
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are 5-ALA and HAL, prodrugs that exhibit no photoac-
tivity until they are metabolized in the cell. After uptake
into the urothelial cell, they are incorporated in the con-
ventional cellular hemobiosynthesis metabolism. The
benefit of PDD to detect more bladder tumors and
reduce residual tumors has been proven by previous
meta-analyses [25–27]. The current study compares
TUR assisted by PPD using 5-ALA or HAL to TUR
assisted by other techniques, but the PpIX precursors’
efficacies were not compared to each other because no
RCT has compared 5-ALA-based PDD and HAL-based
PDD directly.
NBI, another optical enhancement technology, in-
creases the contrast between vasculature and superficial
tissue structures of the mucosa by excluding the red
spectrum of white light. Early reports suggested that
NBI improves detection of bladder tumors including CIS
[24]. Two previous meta-analyses of NBI diagnostic
accuracy demonstrated that NBI-assisted cystoscopy
detects more NMIBC patients and tumors than WLC
and that NBI effectively identifies abnormal lesions
including CIS [28, 29]. While NBI-guided TUR has been
reported to increase imaging quality versus unguided
TUR, neither a meta-analysis nor a RCT comparing the
two techniques has been performed.
A previous conventional pairwise meta-analysis of the
therapeutic outcome in 12 RCTs by Yuan et al. demon-
strated a low OR in the recurrence rate (OR = 0.5, 95 % CI
[0.40–0.62]) after PDD-guided TUR. PDD-guided TUR also
exhibited a low hazard ratio (HR) for recurrence-free
survival (HR = 0.69, 95 % CI [0.53–0.77]). However, the
authors cautioned that their meta-analysis did not distin-
guish TUR using 5-ALA-based PDD from that using HAL-
based PDD and that the heterogeneity could affect the
outcome [27]. Our study involved a network meta-
analysis to overcome the heterogeneity described by
Yuan et al. and was able to also analyze the outcome
after NBI-guided TUR.
Although the recurrence rate of cancers resected
using PDD or NBI has been shown in previous pairwise
meta-analyses to be lower than that resected using
WLC, a superior outcome in terms of progression rate
has not been shown because less data concerning the
rate of progression is available than data concerning
the rate of recurrence; follow-up periods were relatively
short in the enrolled studies. Second, because patients
with high-risk tumors undergo adjuvant immunother-
apy such as BCG instillation, differences in the rate of
progression may be masked. Third, PDD and NBI
exhibit high sensitivity and specificity toward the detec-
tion of CIS [30, 31], with an high area under curve of
0.939 for NBI [28], but these techniques may increase
the rate of unnecessary biopsies.
Our analysis shows that resection using NBI and PDD
did not differ significantly in terms of cancer recurrence
rate. However, PDD-assisted TUR using 5-ALA was
shown superior to that using HAL. In pair-wise meta-
analyses, 5-ALA versus WLC showed an OR of 0.34 and
95 % CI of 0.22–0.51; meanwhile, HAL versus WLC
showed an OR of 0.58 95 % and a CI of 0.45–0.74. In
Fig. 3 Risk of bias summary. Review authors’ judgments for each risk
of bias item for each included study. Green; low risk of bias, Red;
high risk of bias and Yellow; unclear of risk of bias
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regards to ORs, that for 5-ALA was lower than that for
HAL in conventional meta-analysis. In network meta-
analysis, the OR was 0.48, which was similar to that in
conventional meta-analysis; however, the 95 % CI was lon-
ger than that in conventional meta-analysis. The longer
95 % CI for the network meta-analysis was calculated by
indirect comparison based on Bayesian networking.
A meta-analysis compared photosensitizing agents
(5-ALA in 18 reports, HAL in five reports, and both in
two reports) found similar sensitivity and specificity
rates in patients (5-ALA versus HAL: sensitivity = 96 %
versus 90 % and specificity = 56 % versus 80 %, respect-
ively) and biopsies (5-ALA vs. HAL: sensitivity = 95 %
versus 85 % and specificity = 57 % versus 80 %,
Fig. 4 Funnel plots on recurrence (a) and progression rates (b). Little evidence of publication bias was demonstrated by visual or statistical
examination of the funnel plots
Fig. 5 Pairwise meta-analysis for recurrence rate. 5-ALA- and HAL-based PDD, and NBI-guided TUR demonstrated lower recurrence rate than WLC
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Fig. 6 Pairwise meta-analysis for progression rate. No difference in progression rate was observed between cancers resected by all methods investigated
Fig. 7 Network meta-analysis for recurrence and progression rates. a The recurrence rate of cancers resected using 5-ALA-based PDD was lower than
that of those cancers resected using HAL-based PDD and was not significantly different from those resected using NBI. The use of 5-ALA-based PDD,
HAL-based PDD, and NBI all resulted in a lower recurrence rate than WLC. b No difference in progression rate was observed between cancers resected
by all methods investigated
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respectively) [32]. Theoretically, compared to 5-ALA,
HAL penetrates tissue more deeply and exhibits better
accumulation in neoplastic cells [33]. However, the agent
5-ALA was initially developed for PDD and has therefore
been evaluated in more studies than HAL [34]. The data
reviewed seems to indicate some difference between the
use of 5-ALA and HAL. Although the outcomes after
TUR assisted by NBI or PDD do not seem to differ from
each other, NBI-guided TUR is preferable to PDD because
the specificity of PDD significantly decreases in patients
who have undergone a recent instillation [35]. Accord-
ingly, patients whose cancers are suspected to have re-
curred after intravesical therapy were helpful in evaluating
the true specificity of NBI. Whereas PDD requires instilla-
tion of photosensitizing agents via a urethral catheter, NBI
cystoscopy does not require extra invasive steps [36]. Re-
cently, flexible cystoscopy was widely used to detect blad-
der tumors and to monitor bladder cancer patients;
flexible cystoscopy is convenient in an outpatient setting.
Conclusions
Previous RCTs and meta-analyses including the current
study have proven PDD and NBI can enhance the diagnosis
of bladder lesions, guide an adequate resection, and reduce
tumor recurrence. In our network meta-analysis, TUR
assisted by 5-ALA-based PDD demonstrated a lower recur-
rence rate than resection employing HAL. However, recur-
rence after resection using either 5-ALA or HAL was not
significantly different than that after NBI-guided TUR. All
new imaging technologies for bladder cancer were super-
ior to WLC in lowering the recurrence rate, but did not
improve outcome in terms of the progression rate.
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